Novartis : ASCO 2021: strong oncology position confirmed
>A major player in oncology, but no transformative announcements at ASCO 2021 - On the sidelines of the ASCO congress, Novartis’ management yesterday provided an update on its pipeline in oncology. It obviously remains a key therapeutic area for the group, accounting for 31% of sales in 2020. Short term, we note that three compounds, Lu-PSMA-617 (see below), Tislelizumab (2L in NSCLC and œsophagal) and Asciminib (chronic myeloid leukaemia), are due to be filed this ye...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.